Crescent Grove Advisors LLC Acquires Shares of 2,193 DexCom, Inc. (NASDAQ:DXCM)

Crescent Grove Advisors LLC bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,193 shares of the medical device company’s stock, valued at approximately $249,000.

Other large investors have also modified their holdings of the company. Team Hewins LLC lifted its position in DexCom by 3.4% during the first quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock worth $354,000 after buying an additional 83 shares in the last quarter. Bleakley Financial Group LLC boosted its position in shares of DexCom by 1.3% during the 1st quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock valued at $951,000 after acquiring an additional 87 shares during the last quarter. D Orazio & Associates Inc. grew its holdings in shares of DexCom by 0.8% in the fourth quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock valued at $1,534,000 after purchasing an additional 93 shares during the period. Gulf International Bank UK Ltd grew its holdings in shares of DexCom by 0.3% in the first quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock valued at $4,448,000 after purchasing an additional 93 shares during the period. Finally, EverSource Wealth Advisors LLC increased its position in DexCom by 10.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock worth $133,000 after purchasing an additional 98 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Up 0.5 %

DXCM traded up $0.35 on Wednesday, hitting $73.20. 4,150,409 shares of the company were exchanged, compared to its average volume of 3,783,344. The firm has a 50-day moving average price of $97.13 and a two-hundred day moving average price of $117.04. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a market cap of $29.11 billion, a price-to-earnings ratio of 47.23, a price-to-earnings-growth ratio of 2.18 and a beta of 1.16.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The business’s revenue for the quarter was up 15.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.34 earnings per share. On average, equities analysts predict that DexCom, Inc. will post 1.69 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. JPMorgan Chase & Co. cut shares of DexCom from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $145.00 to $75.00 in a research note on Friday, July 26th. Morgan Stanley reduced their target price on DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a research report on Friday, July 26th. Stifel Nicolaus lowered their price target on DexCom from $132.00 to $90.00 and set a “buy” rating for the company in a report on Friday, July 26th. Redburn Atlantic assumed coverage on DexCom in a research report on Thursday, May 30th. They set a “neutral” rating and a $130.00 price objective for the company. Finally, UBS Group decreased their target price on shares of DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $111.63.

Insider Activity at DexCom

In other DexCom news, EVP Michael Jon Brown sold 652 shares of the stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $119.24, for a total value of $77,744.48. Following the transaction, the executive vice president now directly owns 67,560 shares in the company, valued at $8,055,854.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Michael Jon Brown sold 652 shares of DexCom stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $119.24, for a total transaction of $77,744.48. Following the sale, the executive vice president now owns 67,560 shares in the company, valued at $8,055,854.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bridgette P. Heller sold 1,000 shares of the company’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the sale, the director now directly owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The disclosure for this sale can be found here. Insiders have sold 4,135 shares of company stock valued at $446,797 over the last quarter. 0.30% of the stock is owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.